The company announced the new orders during trading hours today, 22 February 2012.

Meanwhile, the BSE Sensex was down 70.59 points, or 0.38% to 18,358.02.

On BSE, 1.54 lakh shares were traded in the counter as against average daily volume of 16,614 shares over the past one quarter.

The stock hit a high of Rs 211 and a low of Rs 190.10 so far during the day. The stock had hit a 52-week high of Rs 227 on 20 July 2011. The stock had hit a 52-week low of Rs 148.45 on 28 March 2011.

The stock had underperformed the market over the past one month till 21 February 2012, rising 8.74% compared with the Sensex's 10.09% gain. The scrip had also underperformed the market in past one quarter, falling 0.51% as against Sensex's 15.57% gain.

The mid-cap company has an equity capital of Rs 15.93 crore. Face value per share is Re 1.

Jubilant Life Sciences said that the contract manufacturing and services division of its subsidiary company -- Jubilant HollisterStier has recently secured contracts with four innovator life science companies for the commercial manufacturing of sterile parenteral products for sale in the US and Europe. These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications, the company said. Commercial transfer to the Jubilant HollisterStier manufacturing facility has commenced for all contracts, Jubilant Life Sciences said in a statement.

Commenting on the contracts, Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier said, We have successfully helped provide safe and effective products to innovator pharmaceutical and biotechnology companies over the years and are committed to do so for these products as well. We are pleased to offer our support in the development and manufacture of highly complex products through the application of leading scientific solutions and utmost dedication to quality and customer service. This expansion of our globally leading parenteral manufacturing capabilities is a further outcome of our strategy to extend our offering across products and geographies.

Commenting on the contracts, Mr Shyam S Bhartia, Chairman & Managing Director and Mr Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, We are pleased with signing of these long term contracts with innovator pharma companies to serve the regulated markets of US and Europe and is a direct result of our increased business development efforts leading to higher utilization of our existing capacity. Jubilant is one of the leading manufacturers of sterile both liquid and lypholized products in North America.

Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences is an integrated pharma and life sciences company headquartered in India. Through its contract manufacturing services division, the company provides its customers global manufacturing services for aseptically fill liquid and lyophilized products, semi-solid and solid dosage forms at its facilities in the US, Canada, and India.

On a consolidated basis, Jubilant Life Sciences reported net loss of Rs 78.39 crore in Q3 December 2011, compared with net profit of Rs 44.11 crore in Q3 December 2010. Net sales rose 25.5% to Rs 1087.17 crore in Q3 December 2011 over Q3 December 2010.

Jubilant Life Sciences is an integrated pharma and life sciences company. It is the largest custom research and manufacturing services (CRAMS) player and a leading drug discovery and development solution provider out of India. The company provides Life Sciences products and services across the value chain. The company has 10 world-class manufacturing facilities across the globe.

Powered by Capital Market - Live News